SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 3,514.10 |
| Enterprise Value ($M) | 3,569.48 |
| Book Value ($M) | 237.12 |
| Book Value / Share | 1.91 |
| Price / Book | 14.82 |
| NCAV ($M) | 169.15 |
| NCAV / Share | 1.36 |
| Price / NCAV | 20.77 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.35 |
| Return on Assets (ROA) | -0.31 |
| Return on Equity (ROE) | -1.08 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.68 |
| Current Ratio | 4.36 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 833.90 |
| Assets | 901.87 |
| Liabilities | 664.75 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | T. Rowe Price Investment Management, Inc. | 2.50 | -52.64 | |
| 13G/A | Wellington Management Group Llp | 12.81 | -5.33 | |
| 13G | BlackRock, Inc. | 5.10 | 0.00 | |
| 13G/A | EcoR1 Capital, LLC | 9.40 | 77.14 | |
| 13G/A | Avoro Capital Advisors LLC | 9.90 | 26.22 | |
| 13G/A | Vanguard Group Inc | 8.06 | 3.73 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 660,192 | 4,249,095 | 15.54 | |
| 243,012 | 929,187 | 26.15 | |
| 228,961 | 977,232 | 23.43 | |
| 303,425 | 1,389,396 | 21.84 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| AMRX – Amneal Pharmaceuticals, Inc. | ANAB – AnaptysBio, Inc. |
| ANNX – Annexon, Inc. | ARQT – Arcutis Biotherapeutics, Inc. |
| ARVN – Arvinas, Inc. |
Financial data and stock pages provided by
Fintel.io